ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Amgen Says ESA Use Dropped By Half In Fourth Quarter.

January 25, 2008

Bladder Cancer Epidemiological Study Involves 3,000 Patients

March 2, 1979

High Cervical Cancer Rates Indicate Access Problems

August 26, 2005

NIH Backs Down Agrees Nurses May Be Hired Into Commissioned Corps

June 13, 1986

Organizations Ask Senate To Increase NCI Appropriations, Order OMB To “Get Nose Out Of Tent”

May 2, 1986

Guest Editorial: A Near-Term Solution: NCI And COG Agree on Plan to Maintain Enrollment

May 23, 2014